Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURTORI-01: Surufatinib plus Toripalimab in Advanced Neuroendocrine Carcinoma
NCT05015621Phase 3Recruiting
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Sep 2021
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of surufatinib and toripalimab in neuroendocrine carcinoma (NEC) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Overall Survival at 2 years. Started Sep 2021; status: recruiting.
02
Drugs
surufatinibtoripalimab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05015621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015621.